PMID- 22037094
OWN - NLM
STAT- MEDLINE
DCOM- 20120710
LR  - 20171116
IS  - 1096-1186 (Electronic)
IS  - 1043-6618 (Linking)
VI  - 65
IP  - 4
DP  - 2012 Apr
TI  - The role of pharmacotherapy in the prevention and treatment of paediatric 
      metabolic syndrome--Implications for long-term health: part of a series on 
      Pediatric Pharmacology, guest edited by Gianvincenzo Zuccotti, Emilio Clementi, 
      and Massimo Molteni.
PG  - 397-401
LID - 10.1016/j.phrs.2011.10.003 [doi]
AB  - The metabolic syndrome (MetS) is defined as a clustering of risk factors 
      predisposing to the future development of cardiovascular disease and Type 2 
      diabetes mellitus (T2DM). Its clinical relevance, above and beyond recognition 
      and treatment of each of the component parts, is still hotly debated--especially 
      within paediatric medicine. Prevention and treatment strategies for adult MetS 
      focus on weight management, as obesity and insulin resistance are known to be at 
      the central axis of the definition, alongside pharmacotherapy of integrally 
      linked conditions such as hypertension and dyslipidaemia. In children and 
      adolescents, however, opportunities for pharmacotherapy are currently limited and 
      interventions aimed at weight management remain the sole treatment paradigm in 
      the majority of cases. This is primarily due to a lack of long-term data relating 
      to the degree of cardiovascular disease and T2DM risk from paediatric MetS, as 
      well as concerns relating to safety and side effect profiles of currently 
      available pharmacotherapies in those who are still growing and developing. 
      Coupled with continuing concern about the recently recognised adverse effects of 
      past and proposed anti-obesity drugs, this indicates that a new era of 
      pharmacotherapy for paediatric MetS is unlikely to be imminent. In fact, the 
      overall paucity of effective current interventions for paediatric MetS is 
      concerning, especially given the fact that approximately 25-33% of all obese 
      paediatric patients likely harbour the condition. It is therefore essential at 
      the present time to concentrate efforts on properly testing the safety and 
      efficacy of currently available products in well-constructed randomised 
      controlled trials in obese adolescents. However, not all obese children and 
      adolescents appear equally at-risk of long-term, weight-related morbidity and a 
      change in emphasis is possibly warranted--one that moves away from simple weight 
      reduction for all and more to a model of reducing long-term risk of 
      cardiovascular disease and T2DM in those at greatest metabolic risk.
CI  - Copyright (c) 2012. Published by Elsevier Ltd.
FAU - Sabin, M A
AU  - Sabin MA
AD  - The Royal Children's Hospital, Murdoch Childrens Research Institute and 
      University of Melbourne, Melbourne, Victoria, Australia. matt.sabin@rch.org.au
FAU - Magnussen, C G
AU  - Magnussen CG
FAU - Juonala, M
AU  - Juonala M
FAU - Cowley, M A
AU  - Cowley MA
FAU - Shield, J P H
AU  - Shield JP
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20111020
PL  - Netherlands
TA  - Pharmacol Res
JT  - Pharmacological research
JID - 8907422
SB  - IM
MH  - Adolescent
MH  - Child
MH  - Humans
MH  - Metabolic Syndrome/*drug therapy/prevention & control
MH  - Obesity/drug therapy
EDAT- 2011/11/01 06:00
MHDA- 2012/07/11 06:00
CRDT- 2011/11/01 06:00
PHST- 2011/10/10 00:00 [received]
PHST- 2011/10/11 00:00 [accepted]
PHST- 2011/11/01 06:00 [entrez]
PHST- 2011/11/01 06:00 [pubmed]
PHST- 2012/07/11 06:00 [medline]
AID - S1043-6618(11)00277-5 [pii]
AID - 10.1016/j.phrs.2011.10.003 [doi]
PST - ppublish
SO  - Pharmacol Res. 2012 Apr;65(4):397-401. doi: 10.1016/j.phrs.2011.10.003. Epub 2011 
      Oct 20.